Analysis by Assay Type (DNA Synthesis Cell Proliferation Assay, Metabolic Activity Cell Proliferation Assay, and Antigen Associated Cell Proliferation Assay), by Method (Colorimetry, Fluorescence, and Others), and by End-User (Pharma & Biotech Companies, Academic & Research Institutes, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035
Buy Now
The global cell proliferation kit market is estimated to garner a revenue of ~USD 700 Million by the end of 2035 by growing at a CAGR of ~12% over the forecast period, i.e., 2023 – 2035. Further, the market generated a revenue of ~USD 500 Million in the year 2022. The growth of the market can be attributed to the rise in the number of biotechnology and pharmaceutical enterprises. Further, the R&D activity, which is being driven by investments made by the pharmaceutical and biopharmaceutical industries in cutting-edge medicines, such as regenerative medicine, is also expected to add to the market growth. In addition, new advancements in regenerative medicine are projected to change pharmaceutical research and development, reviving the entire industry. As per recent estimates, more than 2000 trials for regenerative medicines are ongoing globally, which includes over 1,300 industry-sponsored trials and with almost 250 in Phase III.
In addition to these, factors that are believed to fuel the market growth of cell proliferation kit includes the rise in technological advancement in assay techniques. In order to help attempts to discover new drugs, several test technologies and procedures have emerged. For instance, in an effort to allow the testing of up to 100,000 samples per day, assays in tiny quantities that can be arranged in microtiter plates have been developed. From the first engine driving drug development. Further, the development of several test technologies and procedures has aided in the search for new drugs.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~12% |
|
Base Year Market Size (2022) |
~ USD 500 Million |
|
Forecast Year Market Size (2035) |
~ USD 700 Million |
|
Regional Scope |
|
Growth Drivers
Increasing Rate of Patients Diagnosed with Cancer, and Tumors – On account of the increasing prevalence of cancer, the market is expected to expand more in the upcoming years. According to the World Health Organization, smoking, drinking alcohol, eating poorly, not exercising, and air pollution are risk factors for cancer and other noncommunicable diseases. Approximately, 90–95% cancer cases among Americans can be attributed to lifestyle factors such as cigarette smoking, diet, alcohol, sun exposure, environmental pollutants, infections, stress, obesity, and physical inactivity.
Rising Conscious Towards Healthcare – The anxiety of probable pandemic outbreaks in the future has made people more aware about their health. According to the most recent estimates, more than 80% of the population in Jordan has health insurance (both private and public health insurance).
Growing Government Efforts to Reduce the Cost of Healthcare – Government agencies in both developed and developing nations are expanding their financial contributions to research and development projects and clinical trials addressing various medical diseases. In 2022, there were more than 400 thousand clinical trials registered worldwide.
Growing Usage of Toxicity Testing in the Food Industry – To assess the safety of food and food additives, food safety toxicological tests are a crucial tool. In order to ensure food safety, the food industry has recently improved safety testing techniques that concentrate on microbiological contaminants recently. Further, putting food safety at risk can result in fatalities. Every year, food safety issues cause economic losses for nations all around the world. According to estimates, foodborne infections cost low- to middle-income nations at least $100 billion in losses each year.
Challenges
The global cell proliferation kit market is segmented and analyzed for demand and supply by method into colorimetry, fluorescence, and others. Out of the three types, the colorimetry segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to this technique, as it is easy to retrieve the whole dataset using this method for figuring out cell viability. The calorimetric cell viability kits are used to count the number of living cells in a culture by counting the number of electron receptors that can be reduced. In colorimetric tests, the quantity of a chemical component in a solution is determined by measuring the substance's spectral absorbance at a certain wavelength using a colorimeter (spectrophotometer). For instance, for measuring the number of live cells, colorimetric techniques using tetrazolium salts, such as MTT, XTT, and CCK-8/WST-8, are particularly helpful. The amount of viable cells in the medium may be determined using the tetrazolium salt XTT. Its foundation is the degradation of XTT by mitochondrial dehydrogenase into an orange-yellow formazan molecule that is water soluble. This approach for identifying live cells is accurate since these enzymes become inactive soon after cell death. The calorimetric cell viability kits can identify up to 250,000 viable cells and just 1000 viable cells per well.
The global cell proliferation kit market is also segmented and analyzed for demand and supply by end-user into pharma & biotech companies, academic & research institutes, and others. Amongst these three segments, the pharma & biotech companies segment is expected to garner a significant share. The growth can be attributed to the expanding number of drug discovery projects, and increasing adoption of cloud-based drug discovery platform. Drug discovery strives to continue advancing the development of novel drugs to treat and relieve numerous diseases that are now incurable, as well as common ailments. On the other hand, throughout the last two decades, there has been a surge in both R&D spending and the release of new medications, that is anticipated to boost the segment’s growth in the market.
Our in-depth analysis of the global cell proliferation kit Market includes the following segments:
|
By Assay Type |
|
|
By Method |
|
|
By End User |
|
The North American cell proliferation kit market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the increasing frequency of new cancer cases such as melanoma, urothelial carcinoma, lung cancer, and others in the region. For instance, the most prevalent kind of cancer of the urinary system in the region is bladder cancer. Uroethelial (transitional cell) carcinomas are the most prevalent kind of bladder cancer in the United States, accounting for 90% of all bladder cancer cases. If it's high grade, it has a higher chance of spreading to your lymph nodes, other parts of your body, and your bladder's deeper layers. If detected early, the majority of transitional cell cancers of the renal pelvis and ureter can be treated with the urothelial carcinoma treatment. Further, the most popular form of treatment for kidney transitional cell carcinoma adopted in the region is surgery. Following surgery, you could have radiation or (rarely) chemotherapy, depending on the grade and stage of the malignancy. In addition, while the median age of diagnosis for males is 72 and for women is 75, this tumor affects the elderly rather frequently. The American Cancer Society predicts that there will be roughly 82,000 new cases of bladder cancer in the US in 2023.
The European cell proliferation kit market, amongst the market in all the other regions, is projected to grow with the highest CAGR during the forecast period. The growth of the market can be attributed majorly to the growing cancer incidences in the region. As per the reported data, one in four of all cancer diagnoses occurs in this region. For instance, in all northern and western European nations, prostate cancer was the most often diagnosed cancer in males, whereas lung cancer was the most frequently diagnosed disease in most eastern European nations. Throughout all of Europe, breast cancer is the most often diagnosed cancer in women.
Thermo Fisher Scientific, Inc. deals with EDF Renewables to provide with about 545,000 MWh of renewable power per year from the Millers Branch Solar project in Texas. Further, by 2026, all of the company's current U.S. facilities will be powered entirely by renewable energy with a goal to help the customers make the world healthier, cleaner, and safer.
Biotium, Inc. a provider of a provider of modern life science reagents, and Cell Data Sciences, a maker of RNAstorm and DNAstorm™ kits for RNA/DNA extraction, teamed up to provide a combined pricing for the DNAstormTM and RNAstormTM FFPE extraction kits in comparison to buying each kit separately.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: Increasing rate of patients diagnosed with cancer & tumors, and the rising conscious towards healthcare are the major factors driving the market growth.
Ans: The market is anticipated to attain a CAGR of ~12% over the forecast period, i.e., 2023 – 2035.
Ans: Lack of highly qualified medical personnel in poor economic areas, and dearth of knowledge are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are Thermo Fisher Scientific, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, General Electric Company, PerkinElmer Inc., F. Hoffmann-La Roche AG, Biotium, Inc, and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by assay type, method, end user, and by region.
Ans: The colorimetry segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
